Longeveron Inc (LGVN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.71-3.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LGVN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
We are rapidly approaching the September top line data readout of our ELPIS II Phase 2b clinical trial evaluating laromestrocel in HLHS and look forward to sharing those results.”
Stated in 2 of 2 supplied quarters. Management reported: “We are rapidly approaching the September top line data readout of our ELPIS II Phase 2b clinical trial evaluating laromestrocel in HLHS and look forward to sharing those results.”” “Longeveron is approaching a series of potentially transformative milestones across these programs that have the potential to redefine the trajectory of our business, with the first catalyst, top line results from our Phase 2b clinical trial in HLHS, anticipated in August of this year.”” Revenue was $0.287 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are rapidly approaching the September top line data readout of our ELPIS II Phase 2b clinical trial evaluating laromestrocel in HLHS and look forward to sharing those results.””
“Longeveron is approaching a series of potentially transformative milestones across these programs that have the potential to redefine the trajectory of our business, with the first catalyst, top line…”
Members of the senior management team hosted meetings to explore potential partnership and strategic opportunities for the Company’s four stem cell development programs.
Stated in 2 of 2 supplied quarters. Management reported: ““We have transitioned toward a more capital-efficient, asset-light operating model, with an increased focus on securing strategic licensing partnerships for our stem cell therapy laromestrocel in four development programs.” “Members of the senior management team hosted meetings to explore potential partnership and strategic opportunities for the Company’s four stem cell development programs.”
“Members of the senior management team hosted meetings to explore potential partnership and strategic opportunities for the Company’s four stem cell development programs.”
““We have transitioned toward a more capital-efficient, asset-light operating model, with an increased focus on securing strategic licensing partnerships for our stem cell therapy laromestrocel in fou…”
We currently anticipate our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026, based on our current…
Stated in 2 of 2 supplied quarters. Management reported: “We currently anticipate our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026, based on our current operating budget and cash flow forecast.” “● In February 2026, the Company implemented cash-saving measures to manage cash utilization and extend cash runway.” Operating income was $-6.171 million in 2026-Q2.
“We currently anticipate our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026, based on our current…”
“● In February 2026, the Company implemented cash-saving measures to manage cash utilization and extend cash runway.”
Advance laromestrocel as a treatment for hypoplastic left heart syndrome (HLHS) with top-line Phase 2b clinical trial results and FDA discussions on regulatory path.
Seek strategic collaborations and licensing partnerships to advance laromestrocel development across multiple indications including HLHS, Alzheimer’s, PDCM, and Aging-related Frailty.
Over the trailing year it converted 0.81x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
26 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.